Study S001473

Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT04941521
Study type: INTERVENTIONAL
Phase: PHASE1; PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 3
Start: 2021-06-24
Primary completion: 2021-11-17
Lead sponsor: The University of Texas Health Science Center, Houston
Conditions: Cocaine Use Disorder
Interventions: DRUG:Exenatide 2 mg [Bydureon]; BEHAVIORAL:Drug Counseling
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Feasibility as Assessed by Number of Participants Who Completed Treatment [Week 6]
Drug Safety as Assessed by Total Number of Adverse Events Reported During Treatment [From Week 1 to Week 6]
Clinical Effect of Exenatide as Assessed by Cocaine Use During Treatment as Indicated by Number of Participants With Cocaine-positive Urine Drug Screen Results [From Week 1 to Week 6]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004986	Feasibility of Exenatide, a GLP-1R Agonist, for Treating Cocaine Use Disorder: A Case Series Study. Yammine L, Journal of addiction medicine	2023	Randomized trial	PMID 37579116 DOI	cites ClinicalTrials.gov:NCT04941521; registry reference DERIVED:37579116